The safety and tolerability of the available statins support their use as the first-line treatment
of patients at high risk for coronary heart disease, since the clinical benefits greatly outweigh …

Cancer rates are set to increase at an alarming rate, from 10 million new cases globally in
2000 to 15 million in 2020. Regarding the pharmacological treatment of cancer, we currently …

Objective Our objective was to investigate the interactions between common polymorphisms
in ABCB1, CYP3A4, and CYP3A5 genes and the lipid‐lowering efficacy and safety of the 3 …

The large administrative databases of health plans contain information on drug-related
medical adverse events (AE) and constitute an increasingly powerful tool for the assessment …

Make the most of today's innovative medical therapies, advances in vascular imaging, and
new drugs to improve your patients' cardiovascular health with Vascular Medicine, 2nd …

Drug-induced myopathies and, more rarely, rhabdomyolysis, are a common biological and
clinical setting for clinical rheumatologists. The focus of this chapter is to review (i) the …

The Department of Veterans Affairs (VA) Pharmacy Benefits Management Strategic
Healthcare Group (VA PBM) oversees the formulary for the entire VA system, which serves …

This randomised, double‐blind, placebo (PBO)‐controlled study evaluated the efficacy and
safety of ezetimibe (EZE) co‐administered with ongoing atorvastatin (ATV) therapy in 450 …

Purpose: Cytochrome P450 (CYP) is involved in the metabolism of statins; CYP3A5 is the
main enzyme responsible for lipophilic statin metabolism. However, the evidence of the …

The sequelae of cardiovascular disease contribute significantly to morbidity and mortality in
developed nations. As a class, the statins have been shown to measurably reduce the …